imclone systems incorporated biopharmaceutical company dedicated developing biologic medicines area founded corporate headquarters bridgewater new jersey research headquarters new york october accepted billion acquisition offer eli lilly company became fullyowned subsidiary eli lilly company november prior acquisition traded nasdaq stock exchange symbol imcl imclone lost separate identity former imclone research manufacturing sites renamed eli lilly imclones stock price dropped sharply end drug erbitux experimental monoclonal antibody failed get expected food drug administration fda approval later revealed us securities exchange commission numerous executives sold stock announcement decision close trading december founder samuel waksal arrested insider trading charges informing friends family sell stock attempting sell daughter aliza waksal sold million shares december father jack waksal sold million shares company executives done john b landes general counsel sold million shares december ronald martell vice president marketing sales sold million shares december four executives sold shares following weeks well later samuel waksal pleaded guilty various charges including securities fraud june sentenced seven years three months prison martha stewart founder martha stewart living omnimedia waksal dated stewarts daughter also became embroiled scandal emerged sold imclone shares december day announcement fda decision although stewart maintained innocence found guilty sentenced july five months prison five months home confinement two years probation lying stock sale conspiracy obstruction justice ultimately new clinical trial fda filing prepared imclones partner merck kgaa german merck confused us company similar name resulted fda approval erbitux use colon cancer congressional hearing improprieties imclone held october unveiled culture corruption dating back year imclone ceo waksal first forged signature companys general counsel john landes one three original employees company financial gain nonetheless landes defended waksals illegal actions hearings subcommittee oversight investigations portraying forgery goodfaith misunderstanding representative james greenwood replied children know better mr landes questioning subsequent forgeries waksals part revealed neither landes chief legal officer company companys outside directors reported waksals actions proper authorities made moves waksal removed ceo instead testimony revealed initiated internal investigation never concluded decadeslong tolerance waksals fraud starting companys earliest days provoked representative peter deutsch refer ongoing misconduct wacky fdas february announcement approval use erbitux treatment colorectal cancer reported conclusions drawn trial involving patients responded erbitux used delaying tumor growth months used conjunction standard chemotherapy treatment irinotecan patients responded tumor growth delayed approximately months september bristolmyers squibb committed billion including billion upfront cash payment less imclone due called time drugs blockbuster potential january company put sale failed find buyers likely due fact erbitux time faced significant competition medical marketplace imclone directors withdrew sale company april wall street journal reported bristolmyers squibb co imclone systems inc said cancer drug erbitux failed significantly prolong lives people pancreatic cancer new study marking yet another setback drug industrys efforts find better treatment deadly diseasecitation needed fda approved aforementioned colorectal cancer drug erbitux february may imclone still seeking approval drug known cbs news program minutes aired story two cancer patients struggles obtain compassionate use drug one ultimately succeeded failed despite repeated pleas imclone officials alleged story imclone arbitrary received drug written criteria compassionate october group led billionaire investor carl icahn acquired majority stock thereby giving control within hours announcement interim ceo joseph fischer resigned icahn announced members board directors would yeda research development company set commercialize market products research weizmann institute science challenged aventisowned patent licensed imclone use antiepidermal growth factor receptor antibodies combination chemotherapy slow growth certain tumors socalled filed rhonepoulencrorer issued joseph schlessinger listed firstnamed joseph schlessingers former colleagues weizmann institute particular michael sela claimed come concept alongside schlessinger worked together years yeda challenged aventis patent united states schlessinger testified court idea combining antiegfr antibody lab developed chemotherapy cancer treatment idea however weizmann institute scientists provided extensive documentation developing idea using antibody egfr schlessingers laboratory developed generated given schlessinger claims initiated idea use combination therapy documented research ideas thoroughly leaving forced rely recollections events led patent filing years yeda mounted court ruled yeda sole owners disputed patent us yeda sanofiaventis coown patents foreign counterparts following ruling imclone sanofiaventis agreed settle dispute yeda million company paying yeda return imclone also granted worldwide license technology covered patent agreed pay small royalty erbitux sales yeda july bristolmyers squibb offered take imclone share offer made letter addressed imclones chairman board carl september undisclosed company ceo offered take imclone share financing approach offer conditional results due diligence review imclones business technology undisclosed party completed september september bristolmyers squibb upped offer take imclone addition bristol threatened take offer share holders proxy battle intention replacing current board directors headed carl october imclone agreed acquired eli lilly billion november imclone formally acquired eli lilly nasdaq imcl shares tendered billion imclone fully owned subsidiary eli lilly company drug developed imclone tumor angiogenesis inhibitor cyramza approved fda gastric lilly acquired drug purchase httpsenwikipediaorgwikiimclonesystems